News

Lungcast reflects on this year in pulmonology, looking back at such topics ranging from the American Lung Association ‘State of the Air’ report to artificial intelligence in lung imaging.

The field of allergy medicine this year saw a variety of developments, including the FDA approvals of neffy and omalizumab as well as new data on immunotherapy.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

The field of dermatology saw a wide array of notable developments this year, with highlights including FDA approvals as well as notable clinical trial results.

Neurokinin-3 receptor antagonists such as elinzanetant and fezolinetant provide non-hormonal options for managing hot flashes linked to menopause.

2024 was a historic year in hepatology, characterized by notable hepatic FDA approvals, pipeline developments, new WHO HBV guidelines, and more.

A look back at some of our top coverage in ophthalmology from 2024, including pipeline news and FDA approvals.

Resmetirom made history when it became the first and only FDA-approved MASH drug in 2024, but the pipeline continues to show promise heading into 2025.

The proposed rule seeks to establish and require standardized testing methods to detect and identify asbestos in cosmetic products with talc.

We spotlight 5 impactful regulatory decisions scheduled to occur during the first quarter of 2025.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

From FDA approvals to updated guidelines, 2024 brought transformative advancements in sleep medicine, offering new hope for managing complex sleep disorders.

In this episode of Crisis Point, this year’s news regarding benzene found in acne products is discussed by David Light, Neal Bhatia, MD, and Christopher Bunick, MD, PhD.

Atogepant 60 mg, an oral CGRP receptor antagonist, demonstrated rapid and effective migraine prevention, reducing frequency and improving function in 4 weeks.

Post-hoc analysis findings suggest tenapanor improves both abdominal and bowel symptoms in adult patients with IBS-C.

To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.

These data expanded upon limited real-world data on retention of dupilumab past 2 years of treatment for patients with atopic dermatitis.

A study shows that a lower non-HDL/HDL cholesterol ratio is linked to greater anemia prevalence. A threshold of 4.28 shows a 15% anemia risk drop per unit increase below this value.

Gestational exposure to certain NSAIDs during different trimesters of pregnancy was associated with an increased risk of childhood CKD.

The FDA's approval marks the second generic approval referencing a GLP-1 receptor agonist in as many months for the agency.

Concizumab marks the first subcutaneous injection treatment for hemophilia A or B with inhibitors, demonstrating an 86% reduction in bleeds in pivotal trial data.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

Patients with PSC had worse death, transplant, liver-related mortality, and liver-related decompensation outcomes than PBC and autoimmune hepatitis.

In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.